Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences

New York, August 26, 2015 – Cellectis (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured during several conferences in the coming weeks.

New York, August 26, 2015 – Cellectis (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured during several conferences in the coming weeks.

The Immunotherapy and Vaccine Summit

August 24th to 28th, 2015, Boston, USA

• André Choulika, Ph.D., Chairman and CEO of Cellectis, will be presenting in the panel "Advantages and Disadvantages of Different Gene Editing Technologies" on Thursday, August 27th at 11:45AM.

• Dr Choulika will also give a presentation entitled "Allogeneic Universal CAR-T Cells Engineered With TALEN®" during the session "Merging Gene Editing and Immunotherapy" on Thursday, August 27th at 3:05PM.

• Julien Valton, Ph.D., Senior Scientist at Cellectis, will give a presentation entitled "A Multidrug Resistant Engineered CAR T-Cell for Allogeneic Combination Immunotherapy" during the session "Chimeric Antigen Receptors" on Thursday, August 27th at 11:15AM.

CRI-CIMT-EATI-AACR Immunotherapy Conference

September 16th to 19th, 2015, New York, USA

• Laurent Poirot, Head of Early Discovery at Cellectis, to present a poster entitled "Targeted genome modifications for Improved Adoptive Immunotherapy" on Wednesday, September 16.

• Philippe Duchateau, Chief Scientific Officer at Cellectis, to present a poster entitled "Design of a chimeric antigen receptor (CAR) with controllable function via small molecule" on Friday, September 18.

• Julianne Smith, VP CAR T Development at Cellectis, to present a poster entitled "Allogeneic CAR T-cells for Adoptive Immunotherapy" on Friday, September 18.

Phacilitate Cell & Gene Therapy

September 29th to 30th, 2015, Barcelona, Spain

• Stéphan Reynier, Chief Regulatory and Compliance Officer at Cellectis, to present as a chairperson during the session: "What is the most realistic, practicable supply chain solution for this particular class of products in Europe? What would be most feasible for rare vs. common indications?" This roundtable discussion will take place on Wednesday, September 30th, from 4:20 to 5:30PM.